It will not take much time to sink the ship in mid of journey full of hope with all such burdens like FDF, BIO, CART etc.. this is the clear case of capital misallocation ignoring ground reality.. This will turn Laurus from "Expansive" to "Expensive"
@Atulsingh_asan
Points to ponder:
1. Time value of money
2. Property appreciation
3. Intangible- mental piece and stability in life.. no hassles
4. On an average people used to repay in 8years
5. Rent considered too low and return considered too high 😃
In Netherlands, one get Ice cream with
#Paracetamol
(500mg). When you have a Headache, you don't need to go a pharmacy, instead just take a bowl of Ice cream.
#fwd
Bhasin saab pointrs:
- अनिलजी मै दावे के साथ कह सकता हूँ FII सेलिंग खतम हो गयी है
- Fed has delivrd
- India is in स्वीट स्पॉट
- यह भाव नहीं मिलेंगे
- लेने की चेस्टा कीजिए
- आज फिर 3 buys है.. आप कहे तो मै सुरु करूँ
- एक दो दिन की बात है अनिलजी
- बॉटम बन गया है
#LongLiveBhasinSaab
Pharmaceutical - significance of no. of Employee and its impact on sales and expenses
These are indicative nos. and several factors may impact like location of facilities, pdt mix, segment focus, operational leverage, etc
Sale/emp Cost - give fair indication of overall efficiency
Today many People are saying: money isn’t everything
I would request them to first earn 0.1% of his overall wealth n then throw crap..
Please note health and death r beyond our control
🙏
#RJ
#RakeshJhunjhunwala
#Bigbull
#RIPRakeshJhunjhunwala
This is for the people who are questioning RJ on his current poor health. please refer below article of 2010 to get some insight on his routine and how he managed changes. it is easy to pointout without knowing facts..
#RakeshJhunjhunwala
#AkasaAir
#RJ
Remember “Scale is not a crime” and “being mammoth in US generic” is not a bad thing to happen unless u r S2NL who have minimal understanding and presence in US just like their pumper..
One company m monitoring closely
#Natco
Pharma
As per latest SHP -Promoters, FII, DII increased holdings.. expecting Mar/Jun-2021 kind of SHP pattern in next one year.. Retailers ll be ard 20%
Disc: invested n in loss 😃
Brilliant pieces of advice:
1) Work/Live with those with whom you like working & they like you back - both in personal & professional relationships
2) Money is only & always a faciliator,don't let it define you
New rocket launched yesterday on the eve of Diwali.. Rocket is the modified version of S2NL with all the same parts except 🐕.. PSNL.. official take off of new part on 28th Oct during offline face to face.. Be ready..
Now a days people r blocking for non-performance of stocks.. after mega success of S2NL lovers, baton goes to OCD IDFC First.. God bless 🙏
सबको सन्मति दे भगवान।
Oncology drugs reached $176 bn in sales in 2021. By 2026, cancer drug sales are expected to almost double to $320.6 bn
Cancer drugs are extremely pricey and therefore generate high revenues, with costs of cancer treatment at above $100,000 per patient.
CFO to EBIDTA ratio significance (Rajan Gulati/Anmol)
In the past, investors have lost billions in companies like Satyam and 8K Miles, amongst several others. These companies looked wonderful from an investment standpoint but in reality their books were cooked.
1/n
Let me clarify once again.. m not trolling S2NL n ll buy at appropriate level (atm holding Syngene and Sequent).. m just against the insane pumping with vested interest/limited understanding and glorifying the things beyond its existence disrespecting overall pharma ecosystem 😊
2021-2021: Pumping of S2NL to covid batch investors. S2NL: Sequent, Strides, Solara, Neuland, Laurus.. added Hikal, DCAL, DMCC, SMS in between..
Real n evergreen S2NL: Sun Pharma, Syngene, Natco, Lupin
Misconception feed to innocent investor: Large Base, Compliance threat
Laurus :-)
Company has come up with Annual report. full on capacity expansion against almost questionable growth of overall pharma (~5% volume gwth).. Company is not filing enough ANDA if we decode Annual data.. with formulation capacity of 10bn units supplying 22mn in US
#S2NL
1/n Prime Minister Modi is a great leader, but an even better Marketer
While the world might stereotype India for its
- IT hubs
- Butter chicken
- Slums
- Taj mahal
- Traffic
- Namastes
How the reason of FDF decline could be so different on slides while presenting H1 (Slide-6) and Q2 (slide-10) explanation.. also looks bit contra if we see in totality.. for better clarity, Laurus should provide detailed data with ARV/Non-ARV splits particularly FDF..
पप्पू (बस स्टॉप पर खड़ी लड़की से): क्या तुमने मुझे कोई लोन दिया था?
लड़की: नही तो, क्यों?
पप्पू: पता नही क्यों तुम्हारी तरफ Interest बढ़ता जा रहा है।
#BadJoke
Don’t fall into India pharma brand narratives/small base etc and choose ur bet wisely.. Sun with large base is growing at 11% whereas company like Indoco is struggling at 3.9%.. Glenmark is reporting de growth of 7.5%
First gen entrepreneur psychology never let 1 to sleep till he/she achieve the set target
$1bn target ll back fire. They ll keep chasing topline at the cost of margin
Low margin survival in US gx market is difficult
Interesting time ahead-Q4 ll be decisive
#lauruslabs
#Laurus
.
#Gland
acquisition of
#Cenexi
will provide direct access to Biologicals, MABs, Vaccine (rna and dna) and oral solids.. all 4 facilities (France and Belgium) r USFDA approved.. Last year revenue Euro184mn with 23mn ebitda.. H1 2022 100mn with 19mn revenue.. Looks positive
Accept to karna padega 😜.. maan gaye guru 16% achieved 🙌🏽 ..
worst is peddling through ‘n’ nos of webinar, spaces and tweets.. god bless..
6 months left to reach 100,000 cr mcap
@LaurusLabs
need to work hard to reach innocent investors target.. ek aur “Space” ho jaye?
One last and we will call a day 😃
Day dreaming without business understanding 😜
@AI_Feb21
RSO was dreaming 1 L cr market cap for
#LaurusLab
in 2 years.. its almost 15 months and it was reduced by ~50%..
Simple pharma lesson for companies on Earth:
If No ANDA = Non-existence of so-called CDMO/CRAMS/CMO
ANDA is the source of revenue for feeding other Novel businesses..
Who will consume API/KSM in absence of Finished product mfger?
Need to respect pharma eco-system..
#Period
UV sir started comparing Retail branded business with pumped Hospital business.. “framework” and “thesis” of one specific area to totally different area.. wish to learn such versatile framework..
Top 10 Indian Pharma companies for ANDA approvals 2022
Indian Pharm is playing significant role for Generic Drug Product Approval particularly for sterile products.
Yellow shaded=Indian companies
Today SPARC out-licensed product to Sun pharma.. SPARC will receive $10 mn upfront payment and remaining amount as a milestone.. PDUFA date is in Nov-2022..
Currently, there are no phenobarbital injection products approved by the US FDA for the treatment of seizures in newborns.
Take away of this week from X:
- FI is a myth
- Need atleast $1mn + own house + no debt
- $1mn is not enough after 20 years and need atleast 20-30cr
Conclusion: need to work till next birth to achieve!
#HappyWeekend
.
#Nykaa
good thing on ground level is continuous focus on execution.
1. Expanded Physical reach
2. Logistics through more warehouse space
3. White label expansion -own/acquisition
4. Investment in tech to optimize cost
5. TAM across BPC
Disc: invested n biased
@PRATIKBULANI555
Success of any pharma companies will depend on
1. Execution (no narratives)
2. Entry (market/segment)
3. Expansion (scaleup)
4. Evergreen: Gx (commodity)
5. Ecosystem (pharma is interlinked and one moving part is dependent on other.. output of one is input for other eg API)
Suru sir blocked me as Sequent reached below 135.. he deleted the tweet n blocked me 😃.. intolerant to facts.. i had pinned tweet till it reach 135 n waited for almost 2 months.. god bless everyone 🙏
@ishmohit1
.
#sequent
: Likelihood of further going down as run up only ahead of earnings.. people compared this to Zoetis who is giant as playing through branded theme.. sequent is handicapped coy that is already suffering due to past deed of Mr. AK.. Disc: not invested/no bad intent
Pharma Portfolio to monitor:
- Sun Pharma (850 and blw)
- Natco (700 and blw)
- Zydus Life (370 and blw)
- Strides (280 and blw)
- Sequent (120 and blw)
- Syngene (540 and blw)
- Divis (3200 and blw)
- Marksans (risky but safe blw 46)
#pharma
#investing
#inspiredbyPB
@PRATIKBULANI555
I just opened Demat and is quite easy.. Attaching Snippet covering overall PF split between Eq and MF.. subsequent two snippet on Eq and MF split considering 100%.. In MF SIP is ongoing for Tata Digital, PPFAS, SBI small/Banking, ICICI Value discovery/Health, Quant small/mid
On a closing remark, don’t run behind the jargon.. CDMO in other word is JOB WORK for larger companies.. Mammoth is the scale which company has achieved and it won’t be possible focusing only one set of JOB WORK activities..
One of the biggest product of Gland Pharma - Enoxaparin.. we will see steep competition from BiologicalE in 2023 and onwards.. this will be a biggest blow to Gland Pharma
@tushar9590
Natco 😃.. market is considering gRevlimid as one off opportunity for 1-2 years but company is into all segments with rich and niche pipeline plus presence in mkts like Brazil, Canada, India. Recently diversified into crop science with target of 200-300cr in next 2 yrs